Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 1, 2007, Pages 274-281

  Kawasaki, Toshiyuki ^a   Ishihara, Kotaro ^a   Ago, Yukio ^a   Baba, Akemichi ^a   Matsuda, Toshio ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROTYROSINE; BIOLOGICAL MARKER; DOPAMINE; NORPHENAZONE; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; SCAVENGER; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIPID PEROXIDATION; LOCOMOTION; MESENCEPHALON; MOTOR DYSFUNCTION; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TASK PERFORMANCE;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIPYRINE; BRAIN; CORPUS STRIATUM; DOPAMINE; FREE RADICAL SCAVENGERS; LIPID PEROXIDATION; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; MOTOR ACTIVITY; MPTP POISONING; NEUROPROTECTIVE AGENTS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 34250730257     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.119206     Document Type: Article

References (40)

1. Acuna-Castroviejo D, Cotomontes A, Monti GG, Oritis GG, and Reiter RJ (1997) Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 60:23-29.
2. Antolín I, Mayo JC, Sainz RM, del Brio Mde L, Herrera F, Martin V, and Rodriguez C (2002) Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 943:163-173.
3. Banno M, Mizuno T, Kato H, Zhang G, Kawanokuchi J, Wang J, Kuno R, Jin S, Takeuchi H, and Suzumura A (2005) The radical scavenger edaravone prevents oxidative neurotoxicity induced by peroxynitrite and activated microglia. Neuropharmacology 48:283-290.
4. Björklund A and Lindvall O (1975) Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals. Brain Res 83:531-537.
5. +-induced mitochondrial DNA oxidative damage in vivo and in vitro. J Pineal Res 39:34-42.
6. Cheramy A, Leviel V, and Glowinski J (1981) Dendritic release of dopamine in the substantia nigra. Nature 289:537-542.
7. +. Free Radic Biol Med 13:581-583.
8. Crocker AD (1997) The regulation of motor control: an evaluation of the role of dopamine receptors in the substantia nigra. Rev Neurosci 8:55-76.
9. Crocker SJ, Smith PD, Jackson-Lewis V, Lamba WR, Hayley SP, Grimm E, Callaghan SM, Slack RS, Melloni E, Przedborski S, et al. (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci 23:4081-4091.
10. Ebadi M, Sharma S, Sjavali S, and El Refaey H (2002) Neuroprotective actions of selegiline. J Neurosci Res 67:285-289.
11. Ferger B, Spratt C, Teismann P, Seitz G, and Kuschinsky K (1998) Effects of sytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Eur J Pharmacol 360:155-163.
12. 2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151:35-49.
13. Hayley S, Crocker SJ, Smith PD, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, and Park DS (2004) Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 24:2045-2053.
14. Houkin K, Nakayama N, Kamda K, Noujou T, Abe H, and Kashiwaba T (1998) Neuroprotective effects of the free radical scavenger MCI-186 in patients with cerebral infarction: clinical evaluation using magnetic resonance imaging and spectroscopy. J Stroke Cerebrovasc Dis 7:315-322.
15. Itzhak Y, Martin JL, Black MD, and Ali SF (1998) Effect of melatonin on methamphetamine-and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity and methamphetamine-induced behavioral sensitization. Neuropharmacology 37:781-791.
16. Kawasaki T, Ishihara K, Ago Y, Nakamura S, Itoh S, Baba A, and Matsuda T (2006) Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Eur J Pharmacol 542:92-99.
17. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19:312-318.
18. Kurosaki R, Muramatsu Y, Kato H, and Araki T (2004) Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease. Pharmacol Biochem Behav 78:143-153.
19. Li XJ, Gu J, Lu SD, and Sun FY (2002) Melatonin attenuates MPTP-induced dopaminergic neuronal injury associated with scavenging hydroxyl radical. J Pineal Res 32:47-52.
20. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, and Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5:1403-1409.
21. Mohanakumar KP, Muralikrishnan D, and Thomas B (2000) Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res 864:281-290.
22. Morgan WW and Nelson JF (2001) Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. Brain Res 921:115-121.
23. Munoz A, Rey P, Guerra MJ, Mendez-Alvarez E, Soto-Otero R, and Labandeira-Garcia JL (2006) Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 51:112-120.
24. Muralikrishnan D and Mohanakumar KP (1998) Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 12:905-912.
25. Pierri M, Vaudano E, Sager T, and Englund U (2005) KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 48:517-524.
26. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, and Dawson TM (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 93:4565-4571.
27. Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, Carlson E, Epstein CJ, and Cadet JL (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 12:1658-1667.
28. Riederer P and Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson's disease: a detailed study of influential factors in human brain amine analysis. J Neural Transm 38:277-301.
29. Robertson GS and Robertson HA (1989) Evidence that L-dopa- induced rotational behavior is dependent on both striatal and nigral mechanisms. J Neurosci 9:3326-3331.
30. Satoh K, Ikeda Y, Shioda S, Tobe T, and Yoshikawa T (2002) Edarabone scavenges nitric oxide. Redox Rep 7:219-222.
31. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, and Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823-827.
32. Schulz JB, Matthews RT, Muqit MM, Browne SE, and Beal MF (1995) Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 64:936-939.
33. Sedelis M, Schwarting RK, and Huston JP (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125:109-125.
34. Sriram K, Miller DB, and O'Callaghan JP (2006) Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem 96:706-718.
35. Thomas B and Mohanakumar KP (2004) Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 36:25-32.
36. Tieu K, Ischiropoulos H, and Przedborski S (2003) Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 55:329-335.
37. Van der Schyf CJ, Castagnoli K, Palmer S, Hazelwood L, and Castagnoli N Jr (2000) Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum. Neurotox Res 1:261-269.
38. +-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J 19:1134-1136.
39. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, and Przedborski S (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763-1771.
40. Yoneda Y, Uehara T, Yamasaki H, Kita Y, Tabuch M, and Mori E (2003) Hospital-based study of the care and cost of acute ischemic stroke in Japan. Stroke 34:718-724.